Cargando…

Erratum: Rodriguez et al. Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and Apoptosis. Cancers 2021, 13, 3871

Detalles Bibliográficos
Autores principales:	Rodriguez, Emma, Pei, Guangsheng, Zhao, Zhongming, Kim, Sang T., German, Alexis, Robinson, Prema
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533910/ https://www.ncbi.nlm.nih.gov/pubmed/34680400 http://dx.doi.org/10.3390/cancers13205178

Ejemplares similares

Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and Apoptosis
por: Rodriguez, Emma, et al.
Publicado: (2021)

Analysis of thromboembolic events in head and neck cancer patients who underwent concurrent chemoradiotherapy with cisplatin
por: Cho, Hundo, et al.
Publicado: (2022)

Erratum to: Transportan 10 improves the anticancer activity of cisplatin
por: Rusiecka, Izabela, et al.
Publicado: (2016)

The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N
por: Gallagher, R, et al.
Publicado: (2002)

Erratum to: Synthetic and natural antioxidants attenuate cisplatin-induced vomiting
por: Alam, Javaid, et al.
Publicado: (2017)

In vitro antagonism between cisplatin and vinca alkaloids.
por: Lee, K., et al.
Publicado: (1989)

Erratum to: Cisplatin-induced epigenetic activation of miR-34a sensitizes bladder cancer cells to chemotherapy
por: Li, Heng, et al.
Publicado: (2014)

Substance P Receptor Antagonism: A Potential Novel Treatment Option for Viral-Myocarditis
por: Robinson, Prema, et al.
Publicado: (2015)

Erratum to: Cisplatin-induced mesenchymal stromal cells-mediated mechanism contributing to decreased antitumor effect in breast cancer cells
por: Skolekova, Svetlana, et al.
Publicado: (2016)

Cisplatin, glutathione and the third wheel: a copper-(1,10-phenanthroline) complex modulates cisplatin–GSH interactions from antagonism to synergism in cancer cells resistant to cisplatin
por: Vascellari, Sarah, et al.
Publicado: (2019)

Erratum to: TOPK Activation Exerts Protective Effects on Cisplatin-induced Acute Kidney Injury
por: Zhang, Hui, et al.
Publicado: (2022)

Retraction notice to ‘The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells’ [EBioMedicine 35 (2018) 204–221]
por: Guo, Jiwei, et al.
Publicado: (2021)

Erratum to: A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study
por: Bridgewater, John, et al.
Publicado: (2016)

Erratum for Rodriguez et al., Global Adaptation to a Lipid Environment Triggers the Dormancy-Related Phenotype of Mycobacterium tuberculosis
por: Rodríguez, Juan G., et al.
Publicado: (2014)

Erratum to: Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study
por: Yamaguchi, Kensei, et al.
Publicado: (2012)

circRNA_001275 upregulates Wnt7a expression by competitively sponging miR-370-3p to promote cisplatin resistance in esophageal cancer
por: Zou, Fang-Wen, et al.
Publicado: (2020)

Substance P Antagonism Prevents Chemotherapy-Induced Cardiotoxicity
por: Legi, Ashiq, et al.
Publicado: (2021)

Erratum to: Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma
por: Tanaka, Yoshihiro, et al.
Publicado: (2016)

Heparin antagonizes cisplatin resistance of A2780 ovarian cancer cells by affecting the Wnt signaling pathway
por: Pfankuchen, Daniel Bastian, et al.
Publicado: (2017)

Cisplatin as neoadjuvant chemotherapy in triple negative breast cancer: Exciting early results
por: Goel, Arun Kumar, et al.
Publicado: (2010)

Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin
por: Liang, Sixian, et al.
Publicado: (2014)

Cisplatin-resistant triple-negative breast cancer subtypes: multiple mechanisms of resistance
por: Hill, David P., et al.
Publicado: (2019)

Cisplatin in breast cancer.
por: Willemse, P., et al.
Publicado: (1993)

Erratum: Achilles' heel of triple negative cancer
por: Ocaña, Alberto, et al.
Publicado: (2014)

Erratum: Rodríguez-Navarro, D., et al. Mathematical Model and Calibration Procedure of a PSD Sensor Used in Local Positioning Systems. Sensors 2016, 16, 1484
por: Rodríguez-Navarro, David, et al.
Publicado: (2016)

Synergy, Additivity, and Antagonism between Cisplatin and Selected Coumarins in Human Melanoma Cells
por: Wróblewska-Łuczka, Paula, et al.
Publicado: (2021)

Erratum to: circRNA circSnx12 confers Cisplatin chemoresistance to ovarian cancer by inhibiting ferroptosis through a miR-194-5p/SLC7A11 axis
por: Qin, Kaiyun, et al.
Publicado: (2023)

Erratum: Oligometastases in prostate cancer: restaging stage IV cancers and new radiotherapy options
por: Moreno, Antonio José Conde, et al.
Publicado: (2015)

Cisplatin versus carboplatin in combination with paclitaxel as neoadjuvant regimen for triple negative breast cancer
por: Huang, Liang, et al.
Publicado: (2017)

Correction: Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin
por: Liang, Sixian, et al.
Publicado: (2022)

Erratum: Metformin sensitizes the response of oral squamous cell carcinoma to cisplatin treatment through inhibition of NF-κB/HIF-1α signal axis
por: Qi, Xiaofeng, et al.
Publicado: (2017)

Bismuth Porphyrin Antagonizes Cisplatin-Induced Nephrotoxicity via Unexpected Metallothionein-Independent Mechanisms
por: Wang, Runming, et al.
Publicado: (2020)

Efficacy and Safety of Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin for Treatment of Metastatic Triple-Negative Breast Cancer After Failure with Anthracyclines and Taxanes
por: Wang, Junbin, et al.
Publicado: (2017)

Rodríguez Luna /
por: Rodríguez Luna, Antonio
Publicado: (1995)

Rodríguez Lozano
por: Bergamín, José
Publicado: (1942)

Cisplatin in Liver Cancer Therapy
por: Hamaya, Sae, et al.
Publicado: (2023)

Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer
por: Noronha, Vanita, et al.
Publicado: (2020)

ISL1 promotes cancer progression and inhibits cisplatin sensitivity in triple-negative breast cancer cells
por: Zhang, Yang, et al.
Publicado: (2018)

Cisplatin Loaded Multiwalled Carbon Nanotubes Induce Resistance in Triple Negative Breast Cancer Cells
por: Badea, Madalina Andreea, et al.
Publicado: (2018)

AKT isoforms have discrete expression in triple negative breast cancers and roles in cisplatin sensitivity
por: Wadhwa, Bhumika, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_edng21vqs4p8ku6ps3lv9dvepl